Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study.
From January 1984 to December 1986, 94 patients with unresectable, locally advanced, non-small cell lung cancer (NSCLC) were treated to assess both the efficacy and the toxicity of a combined modality treatment including radiation therapy (45 Gy/15 fractions/3 weeks) and daily low dose cDDP (6 mg/m2). The overall response rate for the 90 evaluable patients was 54.3% with 16.6% of complete responses. At a minimum follow-up of 4 years, the overall median survival time was 12 months. Provided adequate hydration is ensured, the cDDP regimen chosen as a radiosensitizer can be safely combined with radiation therapy.
Trovò
M G
MG
Radiotherapy Division, Centro di Riferimento Oncologico, Aviano, Italy.
Minatel
E
E
Franchin
G
G
Gobitti
C
C
Roncadin
M
M
De Paoli
A
A
Arcicasa
M
M
Boz
G
G
Bortolus
R
R
D000328:Adult; D000368:Aged; D001834:Body Water; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011879:Radiotherapy Dosage; D015996:Survival Rate
D002945:Cisplatin